First experiences with esketamine nasal spray in patients with moderate and severe treatment-resistant depression

Q4 Medicine

Psiquiatria Biologica Pub Date : 2024-11-23 DOI:10.1016/j.psiq.2024.100547

José Miguel Meca García, María Teresa Perní Lasala, María Beret Trancón, Ricardo Jesús Lara Mellado, Antonio José Ureña Caballero, Raquel Fernández Villalobos, José Enrique Romero Baca

{"title":"First experiences with esketamine nasal spray in patients with moderate and severe treatment-resistant depression","authors":"José Miguel Meca García, María Teresa Perní Lasala, María Beret Trancón, Ricardo Jesús Lara Mellado, Antonio José Ureña Caballero, Raquel Fernández Villalobos, José Enrique Romero Baca","doi":"10.1016/j.psiq.2024.100547","DOIUrl":null,"url":null,"abstract":"<div><div>We report 4 cases of female patients with treatment-resistant depression treated with intranasal esketamine. The age of 2 patients were over 50, with only 1 patient in their 20s. The time course of the disease episode ranged from 2 to 4 years, 2 of the cases had psychiatric comorbidity, the time of administration in the patients who completed treatment ranged from 31 to 41 weeks with a discontinuation of treatment due to non-serious but intolerable side effects for one of the patients at 12 weeks. Oral treatment was not substantially modified, with the only notable change being the almost complete withdrawal of benzodiazepines in some cases. The results were satisfactory, with clinical improvement evident in the clinical assessment and in the scales, with 2 patients in complete remission and another in partial remission. Two of these patients returned to work.</div></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"32 2","pages":"Article 100547"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psiquiatria Biologica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1134593424001076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

We report 4 cases of female patients with treatment-resistant depression treated with intranasal esketamine. The age of 2 patients were over 50, with only 1 patient in their 20s. The time course of the disease episode ranged from 2 to 4 years, 2 of the cases had psychiatric comorbidity, the time of administration in the patients who completed treatment ranged from 31 to 41 weeks with a discontinuation of treatment due to non-serious but intolerable side effects for one of the patients at 12 weeks. Oral treatment was not substantially modified, with the only notable change being the almost complete withdrawal of benzodiazepines in some cases. The results were satisfactory, with clinical improvement evident in the clinical assessment and in the scales, with 2 patients in complete remission and another in partial remission. Two of these patients returned to work.

查看原文本刊更多论文

艾氯胺酮鼻腔喷雾剂治疗中度和重度难治性抑郁症的首次经验

我们报告4例女性难治性抑郁症患者鼻用艾氯胺酮治疗。年龄在50岁以上的有2例，20多岁的只有1例。病程从2年到4年不等，其中2例有精神合并症，完成治疗的患者服药时间从31到41 周不等，其中1例患者在12 周时因不严重但无法忍受的副作用而停止治疗。口服治疗没有实质性的改变，唯一值得注意的变化是在某些情况下几乎完全停用苯二氮卓类药物。结果令人满意，临床评估和量表均有明显改善，2例患者完全缓解，1例患者部分缓解。其中两名患者重返工作岗位。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psiquiatria Biologica Medicine-Psychiatry and Mental Health

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Es la Publicación Oficial de la Sociedad Española de Psiquiatría Biológica. Los recientes avances en el conocimiento de la bioquímica y de la fisiología cerebrales y el progreso en general en el campo de las neurociencias han abierto el camino al desarrollo de la psiquiatría biológica, fundada sobre bases anatomofisiológicas, más sólidas y científicas que la psiquiatría tradicional.